Methadone, Buprenorphine or Naltrexone? A Broward County Guide to Opioid Treatment Options

Repeated opioid exposure can produce physical dependence, tolerance, withdrawal and powerful learned patterns of opioid use. Opioid use disorder is therefore not accurately explained as a simple failure of motivation.

Medication can change important parts of this cycle. Depending on the medication, treatment can suppress withdrawal, reduce craving, stabilize opioid-receptor activity or block the effects of subsequently used opioids.

Medication is also relevant to overdose prevention because untreated opioid use disorder exposes people to uncertain opioid potency, fentanyl contamination, interrupted tolerance and repeated cycles of use and abstinence.

Medication does not make counseling, mental-health care or practical recovery planning unnecessary. It creates a more stable clinical platform from which those parts of recovery can be addressed.

Methadone is a long-acting full opioid agonist. It activates the same broad opioid-receptor system involved in heroin, fentanyl and many prescription opioids, but treatment is delivered in a controlled medical framework using a stable medication dose.

When appropriately dosed, methadone can prevent withdrawal, reduce craving and reduce the cycle of repeated intoxication and withdrawal associated with short-acting illicit opioids.

Why Methadone Is Not Simply “Replacing One Drug With Another”

Calling methadone treatment a replacement of one addiction with another confuses physical dependence with compulsive addiction behavior. A patient can be physically dependent on a prescribed medication while functioning normally, following a stable dose and no longer engaging in the uncontrolled drug-seeking behavior associated with untreated opioid use disorder.

Methadone itself is an opioid and requires careful dosing and monitoring. Excessive doses, combining methadone with other sedating substances and unsupervised use can create serious risks. This is why opioid-use-disorder treatment with methadone is delivered through regulated treatment systems.

Buprenorphine is a partial opioid agonist. It binds strongly to opioid receptors but activates them less fully than medications such as methadone or opioids such as heroin and fentanyl.

This pharmacology allows buprenorphine to suppress withdrawal and reduce craving while producing a ceiling effect on some opioid effects. The ceiling effect does not mean overdose is impossible. Combining buprenorphine with alcohol, benzodiazepines or other sedating drugs can still be dangerous.

Why the Timing of Buprenorphine Initiation Matters

Because buprenorphine binds very strongly to opioid receptors, starting it at the wrong point after recent full-agonist opioid use can precipitate withdrawal in a physically dependent patient.

Traditional initiation therefore usually waits for appropriate withdrawal to develop. Clinicians now also use alternative initiation approaches in selected patients, particularly as fentanyl has complicated conventional timing.

Buprenorphine Comes in Several Formulations

Buprenorphine may be available as sublingual tablets or films and as longer-acting injectable products. Some formulations contain buprenorphine alone, while others combine buprenorphine with naloxone.

Suboxone is a brand name for a medication containing buprenorphine and naloxone. Generic buprenorphine/naloxone products are also available.

When Suboxone is taken correctly under the tongue or against the cheek, buprenorphine is the primary medication treating opioid use disorder. The naloxone component is included mainly to discourage certain forms of misuse, particularly injection.

Naloxone is therefore not the ingredient that normally provides the day-to-day treatment effect when the combination medication is taken as prescribed.

Naltrexone works differently from methadone and buprenorphine. It is an opioid-receptor antagonist.

Instead of activating opioid receptors, naltrexone occupies them and blocks or substantially reduces the effects of subsequently used opioids while adequate receptor blockade is present.

Naltrexone does not produce an opioid high and does not maintain opioid physical dependence. This makes it attractive to some patients who prefer an antagonist-based approach.

The tradeoff is that treatment generally cannot begin while the patient remains physically dependent on opioids. Starting naltrexone prematurely can rapidly displace opioids from receptors and trigger precipitated withdrawal.

The exact preparation depends on what opioids have been used, how long they remain active, whether methadone or buprenorphine is involved, individual metabolism and the patient’s clinical condition.

The word “naltrexone” describes the active medication, but delivery systems differ substantially. Evidence from one formulation should not automatically be transferred to another formulation.

Peer-reviewed trials have evaluated sustained-release naltrexone implants in opioid-dependent populations, including randomized studies comparing implant treatment with oral naltrexone or placebo. These results are relevant to the specific formulations and populations studied and should not be generalized automatically to every implant product.

A major U.S. comparative trial of extended-release injectable naltrexone and buprenorphine/naloxone found that starting naltrexone was harder because patients first had to complete opioid withdrawal. Among patients who successfully initiated their assigned medication, both approaches were similarly effective in that trial. The practical challenge of induction therefore matters when comparing antagonist and agonist treatment.

Completing opioid withdrawal removes the immediate physical dependence on continuously circulating opioids. It does not remove the diagnosis, learned behavior, cue responses, emotional patterns or overdose vulnerability associated with opioid use disorder.

This distinction becomes especially important after detox because opioid tolerance can decrease during abstinence. A person who returns to the same quantity of opioid they previously used may now be exposed to a dose their body no longer tolerates.

Medication treatment aims to support the period after withdrawal, not merely the withdrawal itself.

Broward County has an established medication-treatment infrastructure. A resident searching for opioid treatment in Fort Lauderdale does not have to rely on one private clinic or one medication pathway.

Broward Behavioral Health Coalition

The Broward Behavioral Health Coalition currently describes a phased medication-assisted-treatment system that includes induction, intensive outpatient stabilization, maintenance, peer support, medication management and supportive services.

Its current program information specifically lists buprenorphine, buprenorphine/naloxone and naltrexone within Broward medication-treatment programs and also identifies methadone maintenance, buprenorphine maintenance and oral naltrexone among available MAT services.

Broward Addiction Recovery Center

Broward Addiction Recovery Center provides substance-use treatment for adults and currently lists medication-assisted treatment alongside detoxification, outpatient and residential services. Its Fort Lauderdale center identifies detoxification as available 24 hours a day.

Broward Health Hospital Opioid Bridge Program

Broward Health currently operates a Hospital Opioid Bridge Program that can begin medication treatment, including Suboxone, for patients presenting through participating emergency services and then connect them with continuing treatment.

Broward Health also currently advertises free Narcan access through its behavioral-health program.

The names are similar because both medications interact with opioid receptors, but their clinical purposes are very different.

CDC recommends giving naloxone when opioid overdose is suspected, calling 911, supporting breathing where possible and remaining with the person until emergency help arrives.

If a person remains physically dependent on opioids, naltrexone can rapidly displace those opioids from their receptors while blocking further opioid effects.

This can produce precipitated withdrawal, meaning withdrawal begins abruptly and can be more intense than the slower withdrawal that would otherwise occur as opioids leave the body naturally.

FDA prescribing information for extended-release naltrexone warns that reported cases of precipitated withdrawal have sometimes been severe enough to require hospital care.